Hematopoietic growth factors for the treatment of aplastic anemia

Manjusha Kumar, Blanche P. Alter

Research output: Contribution to journalArticlepeer-review

Abstract

The use of hematopoietic growth factors, although well established for the management of chemotherapy-induced neutropenia, remains controversial for the treatment of aplastic anemia and inherited bone marrow failure syndromes. The most commonly used factors are granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and erythropoietin. Newer growth factors such as stem cell factor, thrombopoietin, Flt3 ligand, and interleukins have shown promising results in the laboratory, and some have been used in clinical trials. This article reviews the clinical use of old and new hematopoietic growth factors in acquired and inherited bone marrow failure, and discusses emerging concerns about long term toxicity of these factors.

Original languageEnglish (US)
Pages (from-to)226-234
Number of pages9
JournalCurrent Opinion in Hematology
Volume5
Issue number3
DOIs
StatePublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Hematopoietic growth factors for the treatment of aplastic anemia'. Together they form a unique fingerprint.

Cite this